Genetic testing for inherited cardiac arrhythmias

Hellenic Journal of Cardiology

Volumn 51, Issue 2, 2010, Pages 92-103

  Fowler, Steven J ^a   Cerrone, Marina ^a   Napolitano, Carlo ^a,b,c   Priori, Silvia G ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IRCCS   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Arrhythmias; Cardiac; Cardiomyopathies; Channelopathies; Genetics; Genotyping

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALSEQUESTRIN; RYANODINE RECEPTOR 2;

BRUGADA SYNDROME; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CLINICAL TRIAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DISEASE SEVERITY; DRUG EFFICACY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE COST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE FIBRILLATION; HERITABILITY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INHERITANCE; INHERITED ARRHYTHMOGENIC DISEASE; LONG QT SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE;

ARRHYTHMIAS, CARDIAC; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; BRUGADA SYNDROME; CARDIOMYOPATHY, HYPERTROPHIC; ELECTROCARDIOGRAPHY; GENETIC TESTING; GENOTYPE; HUMANS; LONG QT SYNDROME; TACHYCARDIA, VENTRICULAR;

EID: 77950800704     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Priori SG, Napolitano C. Role of genetic analyses in cardiology: part I: Mendelian diseases: cardiac channelopathies. Circulation. 2006; 113: 1130-1135. (Pubitemid 43754281)
2. Priori, S.G. and C. Napolitano, Genetics of long QT, Brugada and other channelopathies. In: Jalife J, Zipes DP, editors. Cardiac Electrophysiology: From Cell to Bedside. 4th ed. Philadelphia, PA: W.B. Saunders; 2004. p. 8.
3. Lehnart SE, Ackerman MJ, Benson DW, et al. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation. 2007; 116: 2325-2345.
4. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995; 92: 3381-3386.
5. Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation. 1994; 89: 1681-1689.
6. Priori SG, Napolitano C, Vicentini A. Inherited arrhythmia syndromes: applying the molecular biology and genetic to the clinical management. J Interv Card Electrophysiol. 2003; 9: 93-101. (Pubitemid 37441212)
7. Priori SG, Cantù F, Schwartz PJ. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology. Schweiz Med Wochenschr. 1996; 126: 1727-1731.
8. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003; 348: 1866-1874.
9. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005; 2: 507-517. (Pubitemid 40521365)
10. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med. 1998; 339: 960-965.
11. MacCormick JM, McAlister H, Crawford J, et al. Misdiagnosis of long QT syndrome as epilepsy at first presentation. Ann Emerg Med. 2009; 54: 26-32.
12. Mohler PJ, Schott J-J, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 2003; 421: 634-639.
13. Priori SG, Bloise R, Crotti L. The long QT syndrome. Europace. 2001; 3: 16-27.
14. Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995; 92: 2929-2934.
15. Zhang L, Timothy KW, Vincent GM, et al. Spectrum of STT-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation. 2000; 102: 2849-2855.
16. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001; 103: 89-95. (Pubitemid 32050441)
17. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004; 292: 1341-1344. (Pubitemid 39223225)
18. Moss AJ, Shimizu W, Wilde AAM, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation. 2007; 115: 2481-2489. (Pubitemid 46763221)
19. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation. 2002; 105: 794-799. (Pubitemid 34174917)
20. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation. 2007; 116: 1137-1144. (Pubitemid 47360216)
21. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001; 103: 196-200. (Pubitemid 32095402)
22. Lahat H, Pras E, Eldar M. RYR2 and CASQ2 mutations in patients suffering from catecholaminergic polymorphic ventricular tachycardia. Circulation. 2003; 107: e29; author reply e29.
23. Cerrone M, Noujaim SF, Tolkacheva EG, et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2007; 101: 1039-1048. (Pubitemid 350084981)
24. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002; 106: 69-74. (Pubitemid 34747444)
25. Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007; 4: 675-678. (Pubitemid 46655581)
26. Cerrone M, Colombi B, Bloise R, Napolitano C, Priori S, Clinical and molecular characterization of a large cohort of patients affected with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2004; 110 (Suppl II): 2.
27. di Barletta MR, Viatchenko-Karpinski S, Nori A, et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2006; 114: 1012-1019. (Pubitemid 44358877)
28. Tristani-Firouzi M, Jensen JL, Donaldson MR, et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest. 2002; 110: 381-388. (Pubitemid 34847970)
29. Sansone V, Tawil R. Management and treatment of Andersen- Tawil syndrome (ATS). Neurotherapeutics. 2007; 4: 233-237. (Pubitemid 46467540)
30. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992; 20: 1391-1396.
31. Fowler SJ, Priori SG. Clinical spectrum of patients with a Brugada ECG. Curr Opin Cardiol. 2009; 24: 74-81.
32. Thomas K, Grant AO. Ethnicity and arrhythmia susceptibility. J Cardiovasc Electrophysiol. 2008; 19: 427-429.
33. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998; 392: 293-296. (Pubitemid 28155103)
34. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005; 111: 659-670.
35. Ruan Y, Liu N, Priori SG. Sodium channel mutations and arrhythmias. Nat Rev Cardiol. 2009; 6: 337-348.
36. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of- function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007; 115: 442-449. (Pubitemid 46184195)
37. London B, Michalec M, Mehdi H, et al. Mutation in glycerol- 3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation. 2007; 116: 2260-2268. (Pubitemid 350100331)
38. Watanabe H, Koopmann TT, Le Scouarnec S, et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest. 2008; 118: 2260-2268. (Pubitemid 351872343)
39. Delpón E, Cordeiro JM, Núñez L, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol. 2008; 1: 209-218.
40. Shimizu W, Aiba T, Kamakura S. Mechanisms of disease: current understanding and future challenges in Brugada syndrome. Nat Clin Pract Cardiovasc Med. 2005; 2: 408-414. (Pubitemid 41094127)
41. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation. 2001; 104: 3081-3086. (Pubitemid 34014061)
42. Schott JJ, Alshinawi C, Kyndt F, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet. 1999; 23: 20-21.
43. Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA. 2005; 293: 447-454.
44. Frustaci A, Priori SG, Pieroni M, et al. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation. 2005; 112: 3680-3687. (Pubitemid 43739507)
45. Catalano O, Antonaci S, Moro G, et al. Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. Eur Heart J, 2009; 30: 2241-2248.
46. McNair WP, Ku L, Taylor MRG, et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation. 2004; 110: 2163-2167. (Pubitemid 39372495)
47. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002; 105: 1342-1347. (Pubitemid 34260426)
48. Smits JPP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A- related patients. J Am Coll Cardiol. 2002; 40: 350-356. (Pubitemid 34756299)
49. Bezzina CR, Shimizu W, Yang P, et al. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation. 2006; 113: 338-344. (Pubitemid 43803194)
50. Yamada T, Watanabe I, Okumura Y, et al. Atrial electro- physiological abnormality in patients with Brugada syndrome assessed by P-wave signal-averaged ECG and programmed atrial stimulation. Circ J. 2006; 70: 1574-1579. (Pubitemid 44819873)
51. Yokokawa M, Noda T, Okamura H, et al. Comparison of long-term follow-up of electrocardiographic features in Brugada syndrome between the SCN5A-positive probands and the SCN5A-negative probands. Am J Cardiol. 2007; 100: 649-655. (Pubitemid 47223141)
52. Rossenbacker T, Carroll SJ, Liu H, et al. Novel pore mutation in SCN5A manifests as a spectrum of phenotypes ranging from atrial flutter, conduction disease, and Brugada syndrome to sudden cardiac death. Heart Rhythm. 2004; 1: 610-615. (Pubitemid 39462723)
53. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003; 107: 2227-2232. (Pubitemid 36547217)
54. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med. 2008; 5: 158-168.
55. van Dijk SJ, Dooijes D, dos Remedios C, et al. Cardiac myo- sin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009; 119: 1473-1483.
56. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995; 92: 785-789.
57. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003; 42: 1687-1713. (Pubitemid 37383745)
58. Priori SG. Inherited arrhythmogenic diseases: the complexity beyond monogenic disorders. Circ Res. 2004; 94: 140-145.
59. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992; 326: 1108-1114.
60. Charron P, Dubourg O, Desnos M, et al. Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. Eur Heart J. 1998; 19: 139-145.
61. Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004; 44: 1903-1910.
62. Ehlermann P, Weichenhan D, Zehelein J, et al. Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene. BMC Med Genet. 2008; 9: 95.
63. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995; 332: 1058-1064.
64. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. 2001; 104: 1380-1384. (Pubitemid 32880150)
65. Coats CJ, Elliott PM. Current management of hypertrophic cardiomyopathy. Curr Treat Options Cardiovasc Med. 2008; 10: 496-504.
66. Marian AJ. Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol. 2008; 23: 199-205.
67. Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MRG, Towbin JA. Genetic evaluation of cardiomyopathy - a Heart Failure Society of America practice guideline. J Card Fail. 2009; 15: 83-97.
68. Watkins H, Ashrafian H, McKenna WJ. The genetics of hypertrophic cardiomyopathy: Teare redux. Heart. 2008; 94: 1264-1268.
69. Awad MM, Calkins H, Judge DP. Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/ cardiomyopathy. Nat Clin Pract Cardiovasc Med. 2008; 5: 258-267. (Pubitemid 351593909)
70. Sen-Chowdhry S, McKenna WJ. Sudden cardiac death in the young: a strategy for prevention by targeted evaluation. Cardiology. 2006; 105: 196-206. (Pubitemid 43725774)
71. Coonar AS, Protonotarios N, Tsatsopoulou A, et al. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation. 1998; 97: 2049-2058. (Pubitemid 28243668)
72. Syrris P, Ward D, Asimaki A, et al. Desmoglein-2 mutations in arrhythmogenic right ventricular cardiomyopathy: a genotype-phenotype characterization of familial disease. Eur Heart J. 2007; 28: 581-588. (Pubitemid 47355498)
73. Asimaki A, Tandri H, Huang H, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2009; 360: 1075-1084.
74. Saffitz JE. Arrhythmogenic cardiomyopathy and abnormalities of cell-to-cell coupling. Heart Rhythm. 2009; 6 (8 Suppl): S62-65.
75. Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007; 50: 1813-1821. (Pubitemid 350007965)
76. Dalal D, Molin LH, Piccini J, et al. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation. 2006; 113: 1641-1649. (Pubitemid 43754225)
77. Calkins H, Marcus F. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: an update. Curr Cardiol Rep. 2008; 10: 367-375.
78. Bai R, Napolitano C, Bloise R, Monteforte N, Priori SG. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol. 2009; 2: 6-15.
79. Phillips KA, Ackerman MJ, Sakowski J, Berul CI. Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Heart Rhythm. 2005; 2: 1294-1300. (Pubitemid 43064678)
80. Wilde AA, Pinto YM. Cost-effectiveness of genotyping in inherited arrhythmia syndromes: are we getting value for the money? Circ Arrhythm Electrophysiol. 2009; 2: 1-3.
81. Gouas L, Nicaud V, Berthet M, et al. Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population. Eur J Hum Genet. 2005; 13: 1213-1222.
82. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc. 2003; 78: 1479-1487.
83. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A. 2000; 97: 10613-10618.
84. Splawski I, Timothy KW, Tateyama M, et al. Variant of SC- N5A sodium channel implicated in risk of cardiac arrhythmia. Science. 2002; 297: 1333-1336. (Pubitemid 34913168)
85. Pfeufer A, Sanna S, Arking DE, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet. 2009; 41: 407-414.